Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas

Hongyi Li, Jian Tu, Zhiqiang Zhao, Lijuan Chen, Yueting Qu, Hongbo Li, Hao Yao, Xiaoshuai Wang, Dung‐Fang Lee, Jingnan Shen,

Theranostics · 2020 · 31 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

BRCAness might be the common genomic and molecular characteristics of majority of STS cases. PARP-1 and PAR could be potential proper and feasible theranostic biomarkers for assessing HRD in patients. STSs were sensitive to PARPi. Moreover, the combination of niraparib and TMZ showed synergistic effect. Niraparib and TMZ could be a promising targeted therapeutic strategy for patients with STS.

References

32